Skip to main content

Drug Interactions between Bilopaque Sodium and Teslascan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tyropanoate mangafodipir

Applies to: Bilopaque Sodium (tyropanoate) and Teslascan (mangafodipir)

ADJUST DOSING INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.

MANAGEMENT: Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.

References

  1. (2001) "Product Information. Ultravist (iopromide)." Berlex Laboratories
  2. (2001) "Product Information. Visipaque (iodixanol)." Nycomed Inc
  3. (2004) "Product Information. Omniscan (gadodiamide)." Novation

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.